Delivery Order SPE2DB20D3111-SPE2DB25FA8YK
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalation powder, a combination respiratory medication used to treat chronic obstructive pulmonary disease. The contract, valued at $22,743.24 with an ultimate completion date of August 15, 2025, was competitively awarded without set-aside designation and will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $51,571.36 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 (60-count units), a combination inhalation medication used in respiratory disease management. This firm fixed price delivery order, issued on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a non-set-aside competitive award. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $6,700.07 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for TRELEGY ELLIPTA 100-62.5-25 60S, a combination inhalation powder medication used in the treatment of chronic obstructive pulmonary disease. This firm fixed-price delivery order, which is expected to be completed by August 14, 2025, was competitively awarded with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $6,633.02 to AmerisourceBergen Drug Corp on August 4, 2025, for TRELEGY ELLIPTA 100-62.5-25, a respiratory maintenance medication supplied in a 60-dose inhaler configuration. This is a firm fixed price, non-set-aside competitively awarded delivery order with an ultimate completion date of August 5, 2025, and performance based in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $4,665.23 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Trelegy Ellipta 100-62.5-25, a combination inhalation powder used in the treatment of chronic obstructive pulmonary disease. This non-competitive delivery order represents a firm fixed price transaction with a completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,753.67 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of TRELEGY ELLIPTA 200-62.5-25 60S, a combination inhalation medication used in respiratory disease management. The contract is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a $10,547.87 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for TRELEGY ELLIPTA 100-62.5-25 inhalers (60-count). This is a competitively awarded, firm fixed-price delivery order with no set-aside designation, due for completion by August 5, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,930.97 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 60S, a pharmaceutical product for respiratory treatment. The contract, awarded on July 29, 2025, with an ultimate completion date of July 30, 2025, operates under firm fixed price terms with no set-aside designation. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance for this competitively awarded...
- The Defense Logistics Agency awarded a delivery order valued at $1,251.90 to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 60S, a combination inhalation medication used in respiratory disease treatment. This firm fixed-price, non-set-aside contract was awarded on August 15, 2025, with an ultimate completion date of August 18, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $4,886.77 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for TRELEGY ELLIPTA 200-62.5-25 60S, a combination respiratory medication used to treat chronic obstructive pulmonary disease. This non-set-aside competitive award represents a routine pharmaceutical procurement to support military and federal healthcare operations. The delivery order will be performed in Conshohocken, Pennsylvania, with an ultimate completion date...
- SPE2DB20D3111Indefinite Delivery Contract
- SPE2DB20D3111-SPE2DB25FA8YKDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,768.87 to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Trelegy Ellipta 100-62.5-25 (60-unit package), a combination respiratory medication used to treat chronic obstructive pulmonary disease. This firm fixed-price delivery order, which closes on August 19, 2025, was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The order represents a routine pharmaceutical procurement fulfilling the military healthcare supply chain's ongoing medication needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical commodities to support military healthcare systems, the Defense Health Agency, and other federal healthcare organizations globally. The company's federal contract portfolio demonstrates consistent capability in fulfilling competitive pharmaceutical procurement requirements across multiple therapeutic domains, positioning it as a critical supplier for Department of Defense medical supply operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 8/18/25 |